MX2021004342A - Uso de compuesto de carbamato para prevenir, aliviar o tratar neuropatía periférica diabética o neuropatía periférica inducida por quimioterapia. - Google Patents

Uso de compuesto de carbamato para prevenir, aliviar o tratar neuropatía periférica diabética o neuropatía periférica inducida por quimioterapia.

Info

Publication number
MX2021004342A
MX2021004342A MX2021004342A MX2021004342A MX2021004342A MX 2021004342 A MX2021004342 A MX 2021004342A MX 2021004342 A MX2021004342 A MX 2021004342A MX 2021004342 A MX2021004342 A MX 2021004342A MX 2021004342 A MX2021004342 A MX 2021004342A
Authority
MX
Mexico
Prior art keywords
peripheral neuropathy
alleviating
chemotherapy
preventing
carbamate compound
Prior art date
Application number
MX2021004342A
Other languages
English (en)
Inventor
Ji Won Lee
Sun Gwan Hwang
Original Assignee
Sk Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Biopharmaceuticals Co Ltd filed Critical Sk Biopharmaceuticals Co Ltd
Publication of MX2021004342A publication Critical patent/MX2021004342A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se relaciona a un uso que es utilizado para el propósito de prevenir, aliviar o tratar neuropatía periférica diabética o neuropatía periférica inducida por quimioterapia al administrar una composición farmacéutica que contiene un compuesto de carbamato de la fórmula química 1.
MX2021004342A 2018-10-19 2019-10-18 Uso de compuesto de carbamato para prevenir, aliviar o tratar neuropatía periférica diabética o neuropatía periférica inducida por quimioterapia. MX2021004342A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862747841P 2018-10-19 2018-10-19
PCT/KR2019/013701 WO2020080866A1 (ko) 2018-10-19 2019-10-18 카바메이트 화합물의 당뇨병성 말초 신경병증 또는 화학요법 유발 말초 신경병증의 예방, 완화 또는 치료를 위한 용도

Publications (1)

Publication Number Publication Date
MX2021004342A true MX2021004342A (es) 2021-05-31

Family

ID=70284752

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004342A MX2021004342A (es) 2018-10-19 2019-10-18 Uso de compuesto de carbamato para prevenir, aliviar o tratar neuropatía periférica diabética o neuropatía periférica inducida por quimioterapia.

Country Status (11)

Country Link
US (1) US20210379018A1 (es)
EP (1) EP3868375A4 (es)
JP (1) JP7369185B2 (es)
KR (1) KR20210062029A (es)
CN (1) CN112912076A (es)
AU (1) AU2019361856A1 (es)
BR (1) BR112021006586A2 (es)
CA (1) CA3116195A1 (es)
IL (1) IL282287A (es)
MX (1) MX2021004342A (es)
WO (1) WO2020080866A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL300221A (en) * 2020-08-06 2023-03-01 Sk Biopharmaceuticals Co Ltd A solid oral composition containing a carbamate compound and a method for its preparation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7598279B2 (en) * 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
WO2008140197A1 (en) * 2007-05-14 2008-11-20 Sk Holdings Co., Ltd. Novel carbamoyloxy aryl alkan arylpiperazine compound, pharmaceutical compositions comprising the compound and method for treating pain, anxiety and depression by administering the compound
CA2717915A1 (en) * 2008-03-14 2009-09-17 Bionumerik Pharmaceuticals, Inc. Chemoprotective methods and compositions
AU2009348523B2 (en) 2009-06-22 2015-02-26 Sk Biopharmaceuticals Co., Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
US8404461B2 (en) 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
US20150202186A1 (en) * 2014-01-23 2015-07-23 Sova Pharmaceuticals, Inc. CYSTATHIONINE-(gamma)-LYASE (CSE) INHIBITORS FOR TREATING PAIN
KR102489052B1 (ko) * 2016-05-19 2023-01-16 에스케이바이오팜 주식회사 섬유근육통 또는 섬유근육통의 연관된 기능적 증후군을 예방 또는 치료하기 위한 카바메이트 화합물의 용도
KR102421013B1 (ko) * 2016-05-19 2022-07-14 에스케이바이오팜 주식회사 삼차신경통을 예방 또는 치료하기 위한 카바메이트 화합물의 용도
EP3556345B1 (en) * 2016-12-14 2021-09-22 SK Biopharmaceuticals Co., Ltd. Orally disintegrated tablet comprising carbamate compound
WO2018111006A1 (ko) * 2016-12-14 2018-06-21 에스케이바이오팜 주식회사 탈수초성 질환의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도
KR20180068494A (ko) * 2016-12-14 2018-06-22 에스케이바이오팜 주식회사 운동신경세포 질환의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도
KR20190054549A (ko) * 2017-11-14 2019-05-22 에스케이바이오팜 주식회사 말초신경의 나트륨-채널병증을 예방 또는 치료하기 위한 카바메이트 화합물의 용도

Also Published As

Publication number Publication date
EP3868375A4 (en) 2022-06-29
WO2020080866A1 (ko) 2020-04-23
TW202027744A (zh) 2020-08-01
US20210379018A1 (en) 2021-12-09
JP7369185B2 (ja) 2023-10-25
AU2019361856A1 (en) 2021-05-06
BR112021006586A2 (pt) 2021-07-27
CA3116195A1 (en) 2020-04-23
IL282287A (en) 2021-05-31
KR20210062029A (ko) 2021-05-28
JP2022505172A (ja) 2022-01-14
EP3868375A1 (en) 2021-08-25
CN112912076A (zh) 2021-06-04

Similar Documents

Publication Publication Date Title
MX2021006421A (es) Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17).
CR20220363A (es) Compuestos tricíclicos sustituidos
GEP20237506B (en) Pcsk9 antagonist compounds
EA201791261A1 (ru) 1,3-тиазол-2-ил замещенные бензамиды
MX2020013853A (es) Compuestos innovadores.
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
PH12019502851A1 (en) New azaquinoline derivatives
MX2022000945A (es) Composicion para incrementar la expresion de pgc-1alfa.
BR112017005242A2 (pt) composto, composição farmacêutica, e, composto para uso.
PH12018500377A1 (en) Novel annelated benzamides
PH12018500378A1 (en) Novel annelated phenoxyacetamides
NO20180002A1 (en) Aminobenzisoxazole compounds as agonists of A7-nicotinic acetylcholine receptors
MX2021010700A (es) Compuestos utiles en la terapia del vih.
EA202090448A1 (ru) Дигидрооксадиазиноны
WO2016068580A3 (en) Novel pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (kdms)
CO2021001849A2 (es) Nuevo derivado de amina heterocíclico y composición farmacéutica que lo comprende
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
EA201791432A1 (ru) Композиции на основе пролекарства монометилфумарата
DOP2020000077A (es) Nuevo derivado de fenilpiridina y composición farmacéutica que lo contiene
CL2019001618A1 (es) Uso de compuestos de carbamato para prevención, alivio o tratamiento del trastorno bipolar.
MX2021004342A (es) Uso de compuesto de carbamato para prevenir, aliviar o tratar neuropatía periférica diabética o neuropatía periférica inducida por quimioterapia.
PH12020551117A1 (en) Compositions for preventing or treating uveitis
BR112021017710A2 (pt) Composto, composição farmacêutica, método de tratamento
MX2019006941A (es) Uso de compuesto de carbamato para prevenir, aliviar o tratar temblores o el sindrome de temblor.
BR112022001164A2 (pt) Composto, uso de um composto, método para o tratamento ou profilaxia de doenças, composto para uso e composição farmacêutica